Invention Grant
- Patent Title: Sulfonylureas and related compounds and use of same
-
Application No.: US15551264Application Date: 2016-02-16
-
Publication No.: US10538487B2Publication Date: 2020-01-21
- Inventor: Luke O'Neill , Rebecca Coll , Matthew Cooper , Avril Robertson , Kate Schroder
- Applicant: THE UNIVERSITY OF QUEENSLAND , THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF THE BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
- Applicant Address: AU Queensland IE Dublin
- Assignee: THE UNIVERSITY OF QUEENSLAND,THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
- Current Assignee: THE UNIVERSITY OF QUEENSLAND,THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
- Current Assignee Address: AU Queensland IE Dublin
- Agency: Alston & Bird LLP
- Priority: AU2015900507 20150216
- International Application: PCT/AU2016/050103 WO 20160216
- International Announcement: WO2016/131098 WO 20160825
- Main IPC: C07C311/56
- IPC: C07C311/56 ; C07D307/18 ; C07D307/64 ; C07D407/12 ; C07D493/04 ; C07D405/12 ; C07D333/34 ; C07D277/36 ; C07D249/12 ; C07D249/04 ; C07D231/18 ; C07D403/12 ; C07C311/60 ; C07D333/52 ; C07D249/06 ; C07D413/12 ; C07D495/04 ; C07D401/12 ; C07D241/24 ; C07D307/68 ; C07D271/12 ; C07D311/16 ; C07D317/62 ; C07D487/04 ; C07D215/36 ; C07D217/02 ; C07D241/42 ; C07D498/04 ; C07D307/82 ; C07D333/62 ; C07D217/24 ; C07D207/38 ; C07D261/18 ; C07D213/71 ; C07D221/18 ; C07D309/08 ; A61P1/00 ; C07D417/12 ; C07D495/06 ; C07D311/60 ; A61P35/00 ; A61P3/00 ; C07D235/02 ; C07D311/18 ; A61P17/00 ; A61P5/00 ; C07D401/06 ; A61P37/00 ; A61P25/00 ; C07D217/22 ; C07D241/44
Abstract:
The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
Public/Granted literature
- US20180044287A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME Public/Granted day:2018-02-15
Information query
